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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of antivenom on neuromuscular paralysis in people with neurotoxic snake envenoming.
B A C K G R O U N D
Description of the condition
Snakebite leads to significant morbidity and mortality globally,
with an estimated burden of 421,000 to 1,841,000 envenomings
and 20,000 to 94,000 deaths per year. Of this, more than 90% of
envenomings are reported from tropical Asia, sub-Saharan Africa,
and Latin America (Kasturiratne 2008). Venom-induced neuro-
muscular paralysis is one of the major clinical manifestations of
envenoming, predominately by elapid snakes. In some neurotoxic
snakebites, such as by kraits (genus Bungarus) in Asia, life-threat-
ening paralysis occurs in more than 50% of patients (Kularatne
2002; Hung 2009).
Neurotoxic snake venoms primarily affect the neuromuscular
junction causing a disruption of neurotransmission, resulting in
paralysis of the skeletal muscles (Harris 2009; Ranawaka 2013).
Snake venom neurotoxins target multiple sites in the neuromuscu-
lar junction. The majority of the snake venom neurotoxins either
act on the motor nerve terminals (presynaptic) or the nicotinic
acetylcholine receptor on the motor end-plate (postsynaptic).
Presynaptic toxins initially lead to a depletion of the synaptic vesi-
cles and ultimately cause structural damage to the motor nerve
terminals (Logonder 2008; Prasarnpun 2005). This type of insult
is most likely to be treatment resistant, and recovery depends on
the natural regeneration of the nerve terminal, as shown from ex-
perimental studies using presynaptic toxins isolated from krait and
viper venoms (Dixon 1999; Logonder 2008; Prasarnpun 2004;
Prasarnpun 2005). Snake venom postsynaptic neurotoxins com-
petitively bind to the agonist-binding sites of the nicotinic acetyl-
choline receptors on the motor end-plate with high affinity and
poor reversibility, blocking neuromuscular transmission (Ishikawa
1985; Vincent 1998). Some neurotoxic snake venoms, as in kraits,
contain both types of toxins (Rusmili 2014). Several snake venom
toxins act on specific ion channels or affect acetylcholinesterase
activity in the neuromuscular junction (Harris 2009).
Whatever the mechanism, all of these toxins result in the same
clinical effect: neuromuscular weakness, which can range from a
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mild weakness of the eyelid and facial muscles to fatal paralysis
of bulbar and respiratory muscles (Connolly 1995; Isbister 2012;
Johnston 2012; Kularatne 2000; Kularatne 2002; Silva 2016).
In extreme cases, complete neuromuscular paralysis involving all
skeletal muscles of the body can occur (Silva 2016). To sustain
life, mechanical ventilation is essential in people with respiratory
paralysis. Depending on the snake species involved, neuromuscu-
lar paralysis can co-exist with other clinical manifestations of en-
venoming, such as local tissue necrosis seen in cobras, Kularatne
2009, and venom-induced consumptive coagulopathy in vipers,
Sano-Martins 2001, and someAustralasian elapids (Isbister 2012).
The detection and monitoring of the neuromuscular paralysis in
people with snakebite in the clinical setting as well as for research
purposes are almost entirely dependent on the clinical examina-
tion. For this, patients are constantly monitored for clinical fea-
tures of neurotoxicity such as ptosis, ophthalmoplegia, and fa-
cial, neck, bulbar, respiratory, and limb weakness (Isbister 2012;
Johnston 2012; Kularatne 2000; Kularatne 2002). Neurophysio-
logical tests such as single-fibre electromyography have also been
used for this purpose (Silva 2016). However, such tests require
equipment and skills beyond the reach of rural settings, where
snakebites are mostly prevalent.
Description of the intervention
Antivenomshave beenused for the treatment of snakebite formore
than a century (Gutiérrez 2011;WHO2010). They are polyclonal
whole immunoglobulin (IgG) or immunoglobulin fractions (Fab
or F(ab’)2) raised against venom from one (monovalent) or sev-
eral (polyvalent) snake species in other animals, most commonly
horses. The immunised animals are periodically bled and the im-
munoglobulins are separated from the blood using ammonium
sulphate or caprylic acid to produce whole IgG antivenom. Dur-
ing the production of many commercial antivenoms, the whole
immunoglobulins are fractionated by papain or pepsin digestion
to make Fab or F(ab’)2, respectively (Chippaux 2006; Gutiérrez
2011; WHO 2010). Depending on the production protocol, the
immunoglobulins or fractions may be subject to further purifi-
cation involving chromatographic steps and pasteurisation (León
2013). Antivenoms are available in freeze-dried powdered form
(where the powder is reconstituted with sterile water prior to use)
or liquid form. Snake antivenoms are almost always delivered to
the patients via the intravenous route. Antivenom therapy is as-
sociated with adverse reactions, and frequent life-threatening re-
actions are a major problem associated with some antivenoms (de
Silva 2011; de Silva 2015; León 2013).
How the intervention might work
In doses used in the clinical setting, antivenom molecules (poly-
clonal antibodies) likely outnumber the venommolecules (toxins)
in the circulation (Allen 2012; Isbister 2015). The polyclonal na-
ture of the antivenoms means that they contain a range of anti-
bodies or antibody fractions against a range of neurotoxins (both
pre- and postsynaptic), relevant to this review, as well as non-
neurotoxic toxins. These antivenom molecules bind with circulat-
ing toxins, forming large venom-antivenom complexes, trapping
the venom molecules in the circulation (O’Leary 2006; O’Leary
2014). The antibodies likely act via a number of mechanisms, in-
cluding blocking the active site of the neurotoxin molecules, pre-
venting the toxins from interacting with the target site (neuromus-
cular junction) by restricting the movement of the neurotoxins to
the extravascular target sites, and also increasing the elimination
of the toxins (Maduwage 2015). In addition, if the antivenom
molecules are able to distribute from the circulation, they might
be able to reach the neuromuscular junctions and neutralise the
neurotoxins at their target site. However, it is unclear how effec-
tively the whole IgG, F(ab’)2 , or Fab molecules in the antivenoms
can distribute to the neuromuscular junctions.
Presynaptic neurotoxins result in structural damage to the mo-
tor nerve terminals that is irreversible (in the short term). An-
tivenom is therefore unlikely to be able to reverse already es-
tablished presynaptic neurotoxic injury (Harris 2013; Logonder
2008; Prasarnpun 2005). In contrast, postsynaptic neurotoxins
act in a similar way to reversible non-depolarising type neuromus-
cular blockers or muscle relaxants. The reversibility of the bind-
ing of postsynaptic toxins to the nicotinic acetylcholine receptor
varies based on the structural properties of the individual toxins
(Barber 2013). Experimental evidence suggests that specific im-
munoglobulins are able to increase the recovery of the neuromus-
cular junctions from postsynaptic toxin-mediated neuromuscular
block (Gatineau 1988).
Why it is important to do this review
Although antivenom therapy is commonly utilised for neurotoxic
snake envenoming, its effectiveness in preventing or reversing neu-
rotoxicity is less clear and has been questioned in several stud-
ies conducted in different regions (Johnston 2012; Richardson
2007; Theakston 1990; Silva 2016). Recovery of the neurotox-
icity in snake envenoming without antivenom has also been re-
ported (Hung 2009; Pochanugool 1997). In practice, it is doubtful
whether the antivenom could be delivered early enough to prevent
the neurotoxins from reaching neuromuscular junctions. Further-
more, it is unclear whether the antivenoms can speed recovery of
already established neurotoxicity. A recent study of common krait
envenoming demonstrated that even in the patients who received
early antivenom (median 3.5 hours postbite) in an adequate dose
to bind with all circulating venom antigens, antivenomwas unable
to prevent the subsequent development of life-threatening paraly-
sis (Silva 2016). In contrast, a study of taipan bites in Papua New
Guinea found that early administering of antivenom prevented
intubation in a proportion of patients (Connolly 1995).
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O B J E C T I V E S
To assess the effects of antivenom on neuromuscular paralysis in
people with neurotoxic snake envenoming.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill consider randomised controlled trials in humans for inclu-
sion in this review. Of the randomised controlled trials published
after 2010, we will exclude those without an accessible, registered
protocol. We will not consider cluster trials due to issues related
to the unit of analysis.
Types of participants
People of any age, who were bitten or envenomed by neurotoxic
snakes, and have either developed venom-induced neuromuscular
paralysis or have not yet developed venom-inducedneuromuscular
paralysis.Wewill base diagnosis of venom-induced neuromuscular
paralysis on clinical features of neuromuscular paralysis such as
ptosis, ophthalmoplegia, and facial, neck, bulbar, respiratory, and
limb weakness.
Types of interventions
Intravenous administration of snake antivenom regardless of the
type or dose of antivenom. The comparison group will be people
who were not treated with antivenom.
Types of outcome measures
Primary outcomes
1. Mortality as a direct result of neuromuscular paralysis
within 14 days of the snakebite.
Secondary outcomes
1. Incidence of life-threatening paralysis that requires
intubation or mechanical ventilation, or both within 24 hours of
the snakebite.
2. Duration of mechanical ventilation.
3. Incidence of any of the following clinical effects of
neuromuscular paralysis*: ptosis, ophthalmoplegia, weakness of
facial, neck, bulbar, or limb muscles within 48 hours of the
snakebite.
4. Incidence of immediate systemic hypersensitivity reactions
within four hours of antivenom administration.
5. Incidence of serum sickness within 14 days of the
administration of antivenom.
*Neuromuscular paralysis is defined here as presence of at least a
single clinical feature of clinically detectable paralysis (e.g. ptosis,
ophthalmoplegia, facial muscle weakness, neck muscle weakness,
bulbar palsy, respiratory muscle weakness, weakness in upper and
lower limbs).
Information size calculation
To our knowledge, an estimate of the mortality rates due to
venom-induced neuromuscular paralysis is unavailable. However,
the prevalence of life-threatening paralysis (that required intuba-
tion and mechanical ventilation) in krait and taipan envenomings
is 49% to 51% (Trevett 1995; Silva 2016; Kularatne 2002). In a
previous study, antivenom therapy improved the outcome of 3 out
of 6 people with paralysis due to Papuan death adder envenoming
(Lalloo 1996). Based on this, we can assume that themortality rate
for untreated patients (i.e. no antivenom given) due to venom-
induced neuromuscular paralysis in neurotoxic snake envenom-
ing is 50%. Conservatively we expect the antivenom will lower
the mortality by 25% (i.e. half the mortality). Based on the above
assumptions, with a statistical power of 90% and alpha of 0.05,
the information size required is a total of 168 participants (84 par-
ticipants with antivenom treatment and 84 participants without
antivenom treatment).
Search methods for identification of studies
In order to reduce publication and retrieval bias, wewill not restrict
our search by language, date, or publication status.
Electronic searches
The Cochrane Injuries Group’s Information Specialist will search
the following databases:
1. Cochrane Injuries Group Specialised Register (present
version);
2. The Cochrane Library (www.cochranelibrary.com) (latest
issue);
3. Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process &
Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid OLDMEDLINE(R) (1946 to present);
4. Embase Classic + Embase (OvidSP) (1947 to present);
5. ISI Web of Science: Science Citation Index Expanded (SCI-
EXPANDED) (1970 to present);
6. ISI Web of Science: Conference Proceedings Citation
Index-Science (CPCI-S) (1990 to present);
7. ISI BIOSIS Citation Index (1969 to present);
8. KoreaMed (www.koreamed.org) (all available dates);
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9. IndMed (indmed.nic.in) (all available dates);
10. LILACS (Latin American and Caribbean Center on Health
Sciences Database) (lilacs.bvsalud.org/en/) (all available dates);
11. ClinicalTrials.gov (www.clinicaltrials.gov);
12. World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP) (apps.who.int/trialsearch/).
We will adapt the MEDLINE search strategy provided in
Appendix 1 as required for the other databases.
Searching other resources
We will search the reference lists of all relevant studies and con-
tact experts in the field in order to identify ongoing and com-
pleted studies. We will also run a search on regional databases and
journals from South and Southeast Asia, sub-Saharan Africa, and
Latin America, and search the guidelines, conference proceedings,
theses, and other sources of grey literature.
Data collection and analysis
We will perform a systematic review following the instructions
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
Selection of studies
Two review authors (AS and GKI) will independently scan the
titles and abstracts of all articles identified by the search strategy. If
either or both review authors identify an article as possiblymeeting
the inclusion criteria, we will obtain the full text of the published
article. Both review authors will review the full text of each arti-
cle to determine if it meets the inclusion criteria. Disagreements
between the two review authors will be resolved by a third review
author (NB). We will provide details of the included studies in the
appropriate tables within the review. We will report studies not
meeting the inclusion criteria in the ’Characteristics of excluded
studies’ section of the review and the reasons for exclusion in the
’Characteristics of excluded studies’ table. In the event of disagree-
ment between the review authors, we will seek the opinion of a
third review author (NB). For ambiguous studies and where there
are insufficient data, we will attempt to contact the authors of the
articles for further clarification and more information. We will
grade the studies for quality, using the instructions in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Data extraction and management
Two review authors will independently review each article that
meets inclusion criteria, and extract data from the article onto a
standard data extraction form for the following items.
• General information about the article: title of the article,
source, publication year, years the study was conducted, language
of publication.
• Clinical trial characteristics: design, diagnostic
ascertainment, standard care provided, randomisation, allocation
concealment, interventions, dropouts and lost to follow-up,
definitions of outcomes, and methods of outcome assessment.
• Participants: inclusion and exclusion criteria, sample size,
baseline characteristics (participant age, past history of
neuromuscular disorders, clinical severity on enrolment).
• Interventions: type of antivenom (polyvalent or
monovalent), manufacturer, dose of antivenom (number of vials
or milligrams), time administered postbite and duration of
administration.
• Outcomes: mortality*, duration of clinical features of
neuromuscular paralysis including ptosis, ophthalmoplegia,
facial, neck, bulbar, respiratory, and limb weakness, duration of
mechanical ventilation, length of hospital stay, immediate
systemic hypersensitivity reactions, serum sickness.
*In instances where other clinical manifestations of envenoming,
such as coagulopathy and local effects, coexisted and are a likely
cause of mortality rather than neurotoxicity, we will exclude such
cases from the analysis.
Assessment of risk of bias in included studies
Two review authors (AS and GKI) will independently assess the
included studies for risk of bias using the suggested domains and
guidance provided in the Cochrane ’Risk of bias’ tool as detailed
in section 8.5 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).Wewill assess random sequence gen-
eration (selection bias), allocation concealment (selection bias),
blinding of participants and personnel (performance bias), blind-
ing of outcome assessment (detection bias), incomplete outcome
data (attribution bias), selective reporting (reporting bias), and
other sources of bias (in particular funding source). If information
tomake a judgement is insufficient, wewill initially assess domains
as ’unclear risk’ and will attempt to clarify the risk of bias by con-
tacting the study authors. We plan to include all studies irrespec-
tive of the risk of bias. However, we plan to perform a sensitivity
analysis; if the sensitivity analysis shows substantial differences, we
will present alternative estimates that exclude studies with high or
unclear risk of bias.
We will categorise the overall risk of bias of individual studies as
follows:
• low risk of bias (plausible bias unlikely to seriously alter the
results) if all domains were at low risk of bias;
• unclear risk of bias (plausible bias that raises some doubt
about the results) if one or more domains had an unclear risk of
bias; or
• high risk of bias (plausible bias that seriously weakens
confidence in the results) if one or more domains were at high
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risk of bias.
Measures of treatment effect
We will define measures of treatment effects as follows.
Dichotomous data
We will present dichotomous data outcomes as risk ratios (RR)
with 95% confidence intervals (CI) for individual trials.
Continuous data
We will present continuous data outcomes with mean difference
(MD) and 95% CI. As mean differences are easier for clinicians
and readers to interpret, we will calculate mean difference where
possible; we will use standardised mean difference when different
scales are used in the trials.
Ordinal data
We will report ordinal data outcomes such as types of adverse
events and complications depending on the length of the scales
used. If the scale is longer (> 5), wewill treat the data as continuous;
if the scale is short (5 or less), we will combine adjacent categories
to produce dichotomous data.
Unit of analysis issues
The unit of analysis will be the individual participant. To answer
our primary question (does antivenom change mortality due to
neuromuscular paralysis compared to no antivenom treatment),
we will in the first instance simply combine all active intervention
groups of the study into a single group and compare their out-
comes to the control groups(s) not receiving antivenom, whilst
acknowledging the limitations related to the heterogeneity of the
data.
We have excluded cluster randomised trials from the review.We do
not expect to identify cross-over trials as they are an inappropriate
study design for this type of treatment.
Dealing with missing data
We will contact the authors of the original studies if essential data
are missing from their trial reports. If we receive no reply after
eight weeks, we will extract the available data from the published
reports. We will assess the missing data and attrition rates for each
of the included studies and report the number of participants who
are included in the final analysis as a proportion of all participants
in the study.
Assessment of heterogeneity
We will evaluate statistical heterogeneity using the Chi2 test, and
the I2 statistics for quantifying heterogeneity across studies. The
importance of the observed value of I2 depends on (i) magnitude
and direction of effects and (ii) strength of evidence for hetero-
geneity (e.g. P value from the Chi2 test, or a confidence interval
for I2 as outlined inHiggins 2011.We expect high levels of hetero-
geneity due to considerable variation across trials in setting, snake,
intervention, and outcomes; we will consider I2 values of more
than 85% as considerable heterogeneity. The possible elements
of heterogeneity will be included for exploration in a subgroup
analysis, as mentioned in Subgroup analysis and investigation of
heterogeneity. We intend to use the random-effects model to ac-
count for this heterogeneity in any summary estimates of effect.
We will discuss the implications of heterogeneity and how they
relate to external validity in the Discussion.
Assessment of reporting biases
We will refer to systematic differences between reported and un-
reported findings as reporting bias. We will include selective-out-
come reporting assessment as part of the ’Risk of bias’ table and
also under intention-to-treat analysis.
We will assess publication biases by using funnel plots when at
least 10 studies are included in the meta-analysis.
Data synthesis
We will pool dichotomous outcomes such as mortality, risk of
immediate-type hypersensitivity reactions, and risk of serum sick-
ness, and report the RR with 95% CIs. We will use a Mantel-
Haenszel random-effects model for dichotomous data meta-anal-
ysis. For continuous outcomes (duration of mechanical ventila-
tion), we will use an inverse-variance, random-effects model for
the analysis and the mean difference, or the standardised mean
difference if outcomes were measured using different scales. We
will performmeta-analysis if we find two or more studies assessing
the same outcome. If a meta-analysis is not possible, we will write
a narrative summary of the study findings and follow alternative
methods as described in the Cochrane Handbook (Higgins 2011).
Subgroup analysis and investigation of heterogeneity
Where possible (if sufficient data and information are available)
we will perform subgroup analysis based on the following factors,
which are thought to affect outcomes after neuromuscular paral-
ysis.
• Presynaptic versus postsynaptic versus mixed mechanism of
neurotoxic snake envenoming
• Each specific species of snake envenoming
• Type of snake antivenom
• Dose of antivenom
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The immediate hypersensitivity reactions and serum sickness (sec-
ondary outcome measures) are likely to be strongly affected by the
type of snake antivenom, hence we will analyse these based on the
different types of antivenom.
Sensitivity analysis
We will restrict sensitivity analyses to include studies with both
(1) allocation concealment carrying low risk of bias and (2) having
blinded outcome assessment. Different batches of the same an-
tivenom used for the same study may show interbatch variation of
efficacy (leading to variation in effectiveness). Strict implementa-
tion of the random allocation is therefore important inminimising
bias. Some secondary outcomes such as the duration of the clinical
features of paralysis and the duration of mechanical ventilation are
purely based on the clinical decision-making of the treating staff,
hence implementing the blinded outcome assessment is important
in minimising bias. Furthermore, since immediate hypersensitiv-
ity reactions may be affected by pretreatment with epinephrine,
we will carry out sensitivity analysis excluding those participants
treated with epinephrine.
Summarising findings and assessing the quality of the
evidence
We will generate a ’Summary of findings’ table for comparing an-
tivenom versus no antivenom. We will report the following out-
comes in the ’Summary of findings’ table.
1. Mortality as a direct result of neuromuscular paralysis
within 14 days of the snakebite.
2. Incidence of life-threatening paralysis that requires
intubation or mechanical ventilation, or both within 24 hours of
the snakebite.
3. Duration of mechanical ventilation.
4. Incidence of immediate systemic hypersensitivity reactions
within four hours of antivenom administration.
5. Incidence of serum sickness within 14 days of the
administration of antivenom.
We will grade the quality of the evidence in the studies as high,
moderate, low, or very low according to the section 11.5 ofHiggins
2011 using GRADEmethods andGRADEpro software (GRADE
2004; GRADEpro 2015). We will assess the body of evidence
based on the risk of bias of the included studies, directness of the
evidence, inconsistency in results, imprecision of the measure of
effects, and publication bias.
We will provide citations and a rationale for the figures on which
the calculation of assumed and corresponding risks in the ’Sum-
mary of findings’ table are based.
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A P P E N D I C E S
Appendix 1. Search strategy
Ovid MEDLINE (databases) will be searched using the following terms:
1. Snake Bites/
2. (snakebit* or ((snake* or rattlesnake* or viper* or cobra* or asp or asps or mamba* or krait* or adder* or Vipirid* or Vipirin* or
Elapid* or Colubrid* or Hydrophiin* or Laticaudin* or Crotalid* or Crotalin* or Bitis* or Vipera* or Ophiophagus* or Bungarus* or
Crotalus* or Daboia* orMicrurus* orMicruroides* or Adenorhinos* or Atheris* or Cerastes* or Echis* or Eristicophis* orMacrovipera*
or Montatheris* or Proatheris* or Pseudocerastes*) adj3 bit*)).ti,ab,kf.
3. 1 or 2
4. exp Snakes/
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5. (snake* or rattlesnake* or viper* or cobra* or asp or asps or mamba* or krait* or adder* or Vipirid* or Vipirin* or Elapid* or Colubrid*
or Hydrophiin* or Laticaudin* or Crotalid* or Crotalin* or Bitis* or Vipera* or Ophiophagus* or Bungarus* or Crotalus* or Daboia*
or Micrurus* or Micruroides* Adenorhinos* or Atheris* or Cerastes* or Echis* or Eristicophis* or Macrovipera* or Montatheris* or
Proatheris* or Pseudocerastes*).ti,ab,kf,hw.
6. Poisoning/
7. (poison* or toxin* or venom* or envenom* or antivenom*).ti,ab,kf,hw.
8. (neurotoxin* or phospholipase A2*).ti,ab,kf,hw.
9. (4 or 5) and (6 or 7 or 8)
10. exp Snake Venoms/
11. (fasciculin* or dendrotoxin* or alpha-neurotoxin* or crotamine* or bungarotoxin*).ti,ab,kf,hw.
12. Antivenins/
13. or/9-12
14. (neuro* or paralys*).ti,ab,kf.
15. (ptosis* or weakness* or flaccid* or palsy*).ti,ab,kf.
16. exp Paralysis/
17. or/14-16
18. 13 and 17
19. 3 or 18
20. randomized controlled trial.pt.
21. controlled clinical trial.pt.
22. placebo.ti,ab,kf.
23. trial.ti,ab,kf.
24. (RCT or random*).ti,ab,kf.
25. clinical trials as topic.sh.
26. (animals not (humans and animals)).sh.
27. (or/20-25) not 26
28. 19 and 27
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